No consistent effect on refractive outcomes found when using a CTR

Article

Using a capsular tension ring (CTR) implantation has been found to have no consistent effect on refractive outcomes compared with routine phacoemulsification in highly myopic eyes.

Using a capsular tension ring (CTR) implantation has been found to have no consistent effect on refractive outcomes compared with routine phacoemulsification in highly myopic eyes, according to results published in the Journal of Cataract & Refractive Surgery.

Dr Andrea M. Schild et al., University of Cologne, Germany, examined the effect that CTR implantation has on refractive outcomes in patients with high myopia. The researchers drew comparisons between phacoemulsification, IOL implantation with a CTR (CTR group) and without a CTR (control group). Optical biometry was measured using the IOLMaster and the power of the IOL was used to calculate the predicted postoperative spherical equivalent using the Haigis and SRK/T formulas. The main outcomes were the mean error and mean absolute error of the refractive prediction error.

The results demonstrated that the CTR group mean axial length was 29.1 mm and the control group mean axial length was 28.2 mm. No statistically significant difference was noted in mean absolute refractive prediction error between the CTR group and the control group with either formula. However, it was found that there was lower variance in the absolute refractive prediction error in the CTR group with both formulas.

It was revealed that when using a CTR a higher precision in refractive outcomes was obtained and there was no need to alter the IOL power calculation. However, there was no consistent effect on refractive outcomes in highly myopic eyes when using a CTR implant in comparison with phacoemulsification.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.